This paper provides an overview of psychedelic research at the Mayo Clinic in the 1950s and 1960s, focusing on methods, objectives, findings, and ethical practices. We highlight instances where researchers prioritized scientific progress over the autonomy, safety, and equitable treatment of research subjects, and discuss this history in the context of ongoing challenges with informed consent and equity in contemporary psychedelic research.
AlpertJEMcDonaldWMNemeroffCB, et al. (2022) Position statement on the use of psychedelic and empathogenic agents for mental health conditions. APA Official Actions.
2.
BlackmunH (1953) Resume on problems arising out of research in deep electroencephalography. 20March. Rochester, Minnesota: Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic.
3.
BodnárKJKakukP (2019) Research ethics aspects of experimentation with LSD on human subjects: A historical and ethical review. Medicine, Health Care and Philosophy22: 327–337.
4.
BracelandFJ (1966) Howard Phillips Rome, MD, ninety-fourth president, 1965–1966. American Journal of Psychiatry123(1):13–20.
5.
CampbellNDStarkL (2015) Making up ‘vulnerable’people: Human subjects and the subjective experience of medical experiment. Social History of Medicine28(4): 825–848.
6.
CareyF (1955) Doctor tells of work for mentally ill. The Montclair Times, 8December, 24.
DodgeHWJrBickfordRGBaileyAA, et al. (1954) Technics and potentialities of intracranial electrography. Postgraduate Medicine15(4): 291–300.
11.
DyckE (2008) Psychedelic Psychiatry: LSD from Clinic to Campus. Baltimore: Johns Hopkins University Press.
12.
FooteSB (2018) The Crusade for forgotten souls: Reforming Minnesota’s mental institutions, 1946–1954. University of Minnesota Press.
13.
GussJKrauseRSloshowerJ (2020) The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame). PsyArXiv Preprints. DOI: 10.31234/osf.io/u6v9y.
14.
HofferAOsmondH (1959) The adrenochrome model and schizophrenia. The Journal of Nervous and Mental Disease128(1): 18–35.
15.
KlassDWBickfordRG (1992) Reflections on the birth and early development of EEG at the Mayo Clinic. Journal of Clinical Neurophysiology9(1): 2–20.
16.
LiebermanJA (2023) Malady of the Mind: Schizophrenia and the Path to Prevention. New York: Scribner.
17.
MadrasBK (2013) History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia. Journal of the History of the Neurosciences22(1): 62–78.
18.
MangerWMSchwarzBEBaarsCW, et al. (1957) Epinephrine and arterenol (norepinephrine) in mental disease: Plasma and cerebrospinal fluid concentrations. AMA Archives of Neurology & Psychiatry78(4): 396–412.
19.
MartinMJ (1997) A View of the First 50 Years of Psychiatry and Psychology at the Mayo Clinic. Rochester: Mayo Foundation for Medical Education and Research.
20.
MashourGA (2007) From LSD to the IRB: Henry Beecher’s psychedelic research and the foundation of clinical ethics. International Anesthesiology Clinics45(4): 105–111.
Minutes of the Committee on Medical Relations and Publications (1955) 2March. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
24.
Minutes of the Research and Laboratory Committee (1960) 6September. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
25.
Minutes of the Research and Laboratory Committee (1963a) 14March. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
26.
Minutes of the Research and Laboratory Committee (1963b) 9November. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
27.
Minutes of the Sciences Committee (1955a) 1April. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
28.
Minutes of the Sciences Committee (1955b). 15April. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
29.
NicholsDEWalterH (2021) The history of psychedelics in psychiatry. Pharmacopsychiatry54(4): 151–166.
30.
OramM (2016) Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration. History of Psychiatry27(3): 290–306.
31.
PollanM (2019) How to Change Your Mind: What the New Science of Psychedelics Teaches us About Consciousness, Dying, Addiction, Depression, and Transcendence. New York: Penguin.
32.
Principles for Conducting Scientific Investigation Involving Human Subjects (1955) By permission of the Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
33.
RomeHP (1959) Mushrooms, folklore, and experimental psychoses. In: GottliebJSTourneyG (eds.) Scientific Papers and Discussions. Detroit: American Psychiatric Association, 188-201.
RynearsonRRWilsonMRJrBickfordRG (1968) Psilocybin-induced changes in psychologic function, electroencephalogram, and light-evoked potentials in human subjects. Mayo Clinic Proceedings43(3): 191–204.
36.
SchwarzBE (1955a) Berthold Schwarz to Abram Hoffer. 3March. [Letter]. Abram Hoffer Fonds. Courtesy of the Provincial Archives of Saskatchewan.
37.
SchwarzBE (1955b) Berthold Schwarz to Abram Hoffer. 16July. [Letter]. Abram Hoffer Fonds. Courtesy of the Provincial Archives of Saskatchewan.
38.
SchwarzBE (1955c) Berthold Schwarz to Abram Hoffer. 10August. [Letter]. Abram Hoffer Fonds. Courtesy of the Provincial Archives of Saskatchewan.
39.
SchwarzBE (1956) Berthold Schwarz to Abram Hoffer. 30January. [Letter]. Abram Hoffer Fonds. Courtesy of the Provincial Archives of Saskatchewan.
40.
SchwarzBE (1980) Psychic-Nexus. New York: Van Nostran Reinhold Company.
41.
SchwarzBEBickfordRGMulderDW, et al. (1956) Mescaline and LSD-25 in activation of temporal lobe epilepsy. Neurology6(4): 275–280.
42.
SchwarzBEBickfordRGRasmussenWC (1955) Hypnotic phenomena, including hypnotically activated seizures, studied with the electroencephalogram. Journal of Nervous and Mental Disease122(6): 564–574.
43.
SchwarzBESem-JacobsenCWPetersenMC (1956) Effects of mescaline, LSD-25, and adrenochrome on depth electrograms in man. AMA Archives of Neurology & Psychiatry75(6): 579–587.
44.
SchwarzBEBickfordRGRomeHP (1955) Reversibility of induced psychosis with chlorpromazine. Mayo Clinic Proceedings. 30(19): 407–417.
45.
SchwarzBEWakimKGBickfordRG, et al. (1956) Behavioral and electroencephalographic effects of hallucinogenic drugs: Changes in cats on intraventricular injection. AMA Archives of Neurology & Psychiatry75(1): 83-90.
46.
Sciences Committee Duties and Responsibilities (1954) 17November. By permission of Mayo Foundation for Medical Education and Research. Courtesy of the W Bruce Fye Center for the History of Medicine, Mayo Clinic, Rochester, Minnesota.
47.
Sem-JacobsenCW (1959) Depth-electrographic observations in psychotic patients: A system related to emotion and behavior. Acta Psychiatrica Scandinavica34: 412–416.
48.
SmithWRAppelbaumPS (2022) Novel ethical and policy issues in psychiatric uses of psychedelic substances. Neuropharmacology216: 109165.
49.
StraussDde la SalleSSloshowerJ, et al. (2022) Research abuses against people of colour and other vulnerable groups in early psychedelic research. Journal of Medical Ethics48(10): 728–737.
50.
TorbayJ (2023) The work of Donald Ewen Cameron: From psychic driving to MK Ultra. History of Psychiatry34(3): 320–330.
51.
Van ElkMYadenDB (2022) Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews140: 104793.
